188 related articles for article (PubMed ID: 33459081)
1. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H; Cascorbi I
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):369-396. PubMed ID: 33459081
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.
Haufroid V
Curr Drug Targets; 2011 May; 12(5):631-46. PubMed ID: 21039333
[TBL] [Abstract][Full Text] [Related]
4. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Cascorbi I
Pharmacol Ther; 2006 Nov; 112(2):457-73. PubMed ID: 16766035
[TBL] [Abstract][Full Text] [Related]
5. Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).
Gradhand U; Kim RB
Drug Metab Rev; 2008; 40(2):317-54. PubMed ID: 18464048
[TBL] [Abstract][Full Text] [Related]
7. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.
Wada M
Cancer Lett; 2006 Mar; 234(1):40-50. PubMed ID: 16377077
[TBL] [Abstract][Full Text] [Related]
9. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
10. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
11. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of membrane transporters: an update on current approaches.
Sissung TM; Baum CE; Kirkland CT; Gao R; Gardner ER; Figg WD
Mol Biotechnol; 2010 Feb; 44(2):152-67. PubMed ID: 19950006
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of drug transporters.
Franke RM; Gardner ER; Sparreboom A
Curr Pharm Des; 2010; 16(2):220-30. PubMed ID: 19835554
[TBL] [Abstract][Full Text] [Related]
14. Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease.
Silverton L; Dean M; Moitra K
Drug Metabol Drug Interact; 2011; 26(4):169-79. PubMed ID: 22098604
[TBL] [Abstract][Full Text] [Related]
15. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview.
Arrigoni E; Galimberti S; Petrini M; Danesi R; Di Paolo A
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1419-1432. PubMed ID: 27459275
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
17. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.
Colombo S; Soranzo N; Rotger M; Sprenger R; Bleiber G; Furrer H; Buclin T; Goldstein D; Décosterd L; Telenti A;
Pharmacogenet Genomics; 2005 Sep; 15(9):599-608. PubMed ID: 16041239
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
Kim DW; Lee SK; Chu K; Jang IJ; Yu KS; Cho JY; Kim SJ
Epilepsy Res; 2009 Mar; 84(1):86-90. PubMed ID: 19167193
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM; Gardner ER; Gao R; Figg WD
Methods Mol Biol; 2008; 448():41-62. PubMed ID: 18370230
[TBL] [Abstract][Full Text] [Related]
20. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
